New directions for neurodegenerative disease therapy: using chemical compounds to boost the formation of mutant protein inclusions.
Neurodegenerative diseases such as Huntington's, Parkinson's and Alzheimer's diseases are marked by neuronal accumulation of toxic misfolded protein. Developing therapies for these misfolding diseases requires finding chemical compounds that can either clear toxic misfolded protein, or can protect neurons from their impact. Such compounds could not only provide the starting points for potential drugs, but could also provide valuable research tools for untangling the complexities of the disease process. Until now, chemical screens for these diseases have focused on finding compounds that prevent aggregation of mutant protein. We recently published a compound, B2, which promotes the formation of large inclusions by mutant Huntingtin and alpha-synuclein, while rescuing some of the toxic effects of these proteins. As inclusions were long believed to be toxic to cells, this contradicts previous therapeutic approaches. At the same time, the results support growing evidence for the protective effects of inclusions. In this review, we discuss these results, and place them in the context of ongoing therapeutic discovery efforts for Huntington's disease and other neurodegenerative diseases.
Bodner
Ruth A
RA
Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA. rbodner@mit.edu
Housman
David E
DE
Kazantsev
Aleksey G
AG
D006801:Humans; D002479:Inclusion Bodies / Q000187:drug effects*; D050505:Mutant Proteins / Q000737:chemistry*; D019636:Neurodegenerative Diseases / Q000188:drug therapy* / Q000209:etiology; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use; D009600:Nitroquinolines / Q000627:therapeutic use; D051844:alpha-Synuclein / Q000187:drug effects
D050505:Mutant Proteins; D018696:Neuroprotective Agents; D009600:Nitroquinolines; D051844:alpha-Synuclein